GlobeNewswire Inc.··NaStarton Advances Subcutaneous Lenalidomide Program With Phase 2a Multiple Myeloma Trial Launch
Starton launches Phase 2a trial for subcutaneous lenalidomide delivery in multiple myeloma, comparing three dose levels against standard oral Revlimid treatment.
BMYCELGrclinical developmentmultiple myeloma